Drugs & Targets Purdue Ventures invests in antibody-based cancer therapeutics company April 21, 2023Vol.49 No.16
Drugs & Targets mRNA cancer vaccine + Keytruda receives PRIME scheme designation from EMA for adjuvant treatment of high-risk stage 3/4 melanoma April 14, 2023Vol.49 No.15
Drugs & Targets ArteraAI and ACS form collaboration to use AI for designing personalized therapy April 14, 2023Vol.49 No.15
Drugs & Targets Adaptive Biotechnologies, Takeda form translational collaboration to measure minimal residual disease April 14, 2023Vol.49 No.15
Drugs & Targets Caris Life Sciences, Flare Therapeutics form precision oncology collaboration April 14, 2023Vol.49 No.15
Drugs & Targets University of Florida Health, Nuance Communications form collaboration focused on AI in radiology April 14, 2023Vol.49 No.15
Drugs & Targets FDA approves Keytruda + Padcev for first-line treatment of certain patients with locally advanced or metastatic urothelial cancer April 07, 2023Vol.49 No.14
Drugs & Targets FDA grants full approval indication for Keytruda for certain patients with advanced MSI-H or dMMR solid tumors March 31, 2023Vol.49 No.13
Drugs & Targets Libtayo + chemo approved by EC for first-line treatment of advanced PD-L1-positive NSCLC March 31, 2023Vol.49 No.13
Drugs & Targets Predictive Oncology and Integra Therapeutics form collaboration focused on gene therapy March 31, 2023Vol.49 No.13
